Your browser doesn't support javascript.
loading
Long-term Outcomes and Survival in Moderate-severe Portopulmonary Hypertension After Liver Transplant.
Sadd, Corey J; Osman, Fauzia; Li, Zhanhai; Chybowski, Amy; Decker, Catherine; Henderson, Bruce; Goss, Kara N; Hammel, Laura L; Runo, James R.
Affiliation
  • Sadd CJ; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.
  • Osman F; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.
  • Li Z; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.
  • Chybowski A; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.
  • Decker C; School of Pharmacy, University of Wisconsin-Madison, Madison, WI.
  • Henderson B; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.
  • Goss KN; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.
  • Hammel LL; Department of Anesthesiology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.
  • Runo JR; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.
Transplantation ; 105(2): 346-353, 2021 02 01.
Article in En | MEDLINE | ID: mdl-32235258
ABSTRACT

BACKGROUND:

Portopulmonary hypertension is present in an estimated 5.3% to 8.5% of liver transplant candidates. Untreated, 5-year survival is estimated between 14% and 28%. Moderate-severe disease is a contraindication to liver transplant due to the high perioperative mortality, but patients optimized with pulmonary vasodilator therapy can become eligible for transplant. There is minimal data regarding posttransplant outcomes and ability to discontinue pulmonary vasodilator therapy posttransplant.

METHODS:

We performed a single-center retrospective analysis to evaluate long-term outcomes of patients with moderate-severe portopulmonary hypertension who were optimized with pulmonary vasodilator therapy, became eligible for liver transplant, and subsequently underwent transplant. We identified 24 patients optimized with pulmonary vasodilator therapy who underwent subsequent liver transplantation and 25 patients who were treated with pulmonary vasodilator therapy alone.

RESULTS:

In the transplanted cohort, 1-year survival from portopulmonary hypertension diagnosis date 95.8%, 3-year survival 90.9%, and 5-year survival 90.9%. Posttransplant; 1-, 3-, and 5-year survival was 86.9%. Among transplanted patients, 41.6% (10/24) were optimized with nonparenteral therapy. Following transplantation, 100% (14/14) of the surviving patients were able to discontinue parenteral therapy; median time 7.2 months (interquartile range 5.1-8.9 mo), while 61.9% (13/21) were able to discontinue pulmonary vasodilator therapy altogether; median time 13.9 months (interquartile range 5.1-17.6 mo).

CONCLUSIONS:

Patients who are optimized with pulmonary vasodilator therapy before liver transplant can have excellent long-term outcomes posttransplant. Oral pulmonary vasodilator therapy can be effective treatment to qualify a patient for transplant, and the majority are able to wean from pulmonary vasodilator therapy entirely posttransplant.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Artery / Vasodilator Agents / Liver Transplantation / Portal Pressure / End Stage Liver Disease / Arterial Pressure / Pulmonary Arterial Hypertension / Hypertension, Portal / Antihypertensive Agents Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Transplantation Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Artery / Vasodilator Agents / Liver Transplantation / Portal Pressure / End Stage Liver Disease / Arterial Pressure / Pulmonary Arterial Hypertension / Hypertension, Portal / Antihypertensive Agents Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Transplantation Year: 2021 Document type: Article
...